Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial - Associated Press

Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial  Associated Press

KENILWORTH, N.J.--(BUSINESS WIRE)--Dec 20, 2018--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EAQ8Zw